%0 Journal Article
%A Martinez-Lopez, Joaquin
%A Alonso, Rafael
%A Wong, Sandy W
%A Rios, Rafael
%A Shah, Nina
%A Ruiz-Heredia, Yanira
%A Sanchez-Pina, Jose Maria
%A Sanchez, Ricardo
%A Bahri, Natasha
%A Zamanillo, Irene
%A Poza, Maria
%A Buenache, Natalia
%A Encinas, Cristina
%A Juarez, Luis
%A Miras, Fatima
%A Collado, Luis
%A Barrio, Santiago
%A Martin, Thomas
%A Cedena, Maria Teresa
%A Wolf, Jeffrey
%T Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
%D 2021
%U http://hdl.handle.net/10668/18386
%X The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM has been underexplored to date. In this retrospective study, we present the results from a multinational and multicenter series of 400 patients with MRD monitoring during front-line therapy with the aim of exploring how clinical decisions made based on those MRD results affected outcomes. As expected, achievement of MRD negativity at any point was associated with improved PFS versus persistent MRD positivity (median PFS 104 vs. 45 months, p 
%K Measurable residual disease
%K Minimal residual disease
%K Multiple myeloma
%~